2-cyclopropyl-2H-indazole | 1311194-77-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡唑类
• 英文名称: 2-cyclopropyl-2H-indazole
• 英文别名: 2-cyclopropylindazole
• CAS: 1311194-77-0
• 化学式: C₁₀H₁₀N₂
• 分子量: 158.203
• InChiKey: BBFWGAJQFYQTGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  邻溴苯甲醛 、 环丙胺 在 copper(l) iodide 、 sodium azide 、 四甲基乙二胺 作用下， 以 二甲基亚砜 为溶剂， 反应 12.0h， 以63%的产率得到2-cyclopropyl-2H-indazole
  参考文献：
  名称：

  Consecutive Condensation, C–N and N–N Bond Formations: A Copper- Catalyzed One-Pot Three-Component Synthesis of 2H-Indazole

  摘要：

  2H-Indazoles are synthesized using copper-catalyzed, one-pot, three-component reactions of 2-bromobenzaldehydes, primary amines, and sodium azide. A copper catalyst plays the key role in the formation of C-N and N-N bonds. This method has a broad substrate scope with a high tolerance for a variety of functional groups.

  DOI：

  10.1021/ol201409j

文献信息

• NOVEL COMPOUNDS AND COMPOSITIONS FOR INHIBITION OF FASN
  申请人：FORMA THERAPEUTICS, INC.

  公开号：US20160002188A1

  公开（公告）日：2016-01-07

  The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

  本发明涉及用于抑制FASN的化合物和组合物，它们的合成，应用和解毒剂。本发明的一个示例化合物如下所示：
• Compounds and compositions for inhibition of FASN
  申请人：FORMA Therapeutics, Inc.

  公开号：US10399951B2

  公开（公告）日：2019-09-03

  The present invention relates to compounds and compositions for inhibition of FASN, their synthesis, applications, and antidotes.

  本发明涉及抑制 FASN 的化合物和组合物、其合成、应用和解毒剂。
• METHODS OF USING FASN INHIBITORS
  申请人：FORMA Therapeutics, Inc.

  公开号：US20170312273A1

  公开（公告）日：2017-11-02

  The present disclosure relates to methods of treating, preventing or ameliorating a TH17- or CSF1-mediated disease or disorder such as cancer, immunological disorders, and obesity by administering to a patient in need thereof a therapeutically effective amount of a FASN inhibitor, or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof.
• TREATMENT OF GLIOBLASTOMA WITH FASN INHIBITORS
  申请人：FORMA Therapeutics, Inc.

  公开号：US20210252011A1

  公开（公告）日：2021-08-19

  The present disclosure relates to methods of treating glioblastoma by administering to a patient in need thereof a FASN inhibitor.